Blood thinner dose comparison for severe injury patients in intensive care
Part of Heart & circulation, Injuries & trauma clinical trials.
This study compares two doses of a blood thinner (enoxaparin) to see which better prevents blood clots in patients with severe injuries who are in the intensive care unit. It helps doctors choose the best dose to keep you safe and healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are in the intensive care unit after a serious injury, expected to stay for more than 48 hours.
- You will be receiving a blood-thinning medication called low-molecular-weight heparin (LMWH) as part of your care.
- You must be affiliated with the French social security system or European equivalent (CEAM).
- You must not have severe kidney disease (creatinine clearance ≤30 mL/min).
- Your body weight must be between 45 kg and 100 kg (about 99 to 220 lbs).
- You must not be at high risk of bleeding (for example, active bleeding, recent brain surgery, or a bleeding disorder like hemophilia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the blood thinner enoxaparin (Lovenox) is absorbed in people with severe obesity when injected into two different body areas. It aims to see if the standard preventive dose works well, potentially improving clot prevention for people your size.
This Phase 2 trial studies whether giving antithrombin can better prevent harmful blood clots (venous thromboembolism) after serious injuries. The goal is to reduce clot risk while you’re in the trauma ICU or step-down unit.
This trial compares two blood thinners (rivaroxaban pills versus LMWH shots) to see which is better at preventing blood clots in people with leg injuries that require a cast or brace. If you qualify, you can receive one of these treatments while your leg heals.
This study looks at how a common blood thinner (enoxaparin) is processed in the body of ICU patients with kidney failure, including those on dialysis. The goal is to make sure the dose is safe and effective for preventing blood clots in this fragile group.
This trial tests whether a daily injection of a blood-thinning medicine called enoxaparin (Lovenox) can safely prevent dangerous blood clots in teens who are critically ill in the intensive care unit with an IV line and an infection or inflammation. It may help reduce the risk of blood clots without causing excess bleeding.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.